Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MD Anderson Oncologist Stephen Hahn Is Trump’s First Choice For FDA Commissioner: Reports

Executive Summary

Media reports say President Trump will nominate Stephen Hahn, an oncologist serving as chief medical executive of MD Anderson Cancer Center, as the next US FDA commissioner. This comes despite a group of former agency chiefs’ support for the current acting commissioner, Ned Sharpless, to permanently fill the spot.

You may also be interested in...



Trump Nominates Hahn As New FDA Commish; Acting Head Sharpless Returns To NCI

The White House has announced President Trump’s intent to nominate MD Anderson’s Stephen Hahn as the next FDA commissioner. The position has been held by acting commissioner Ned Sharpless for the past seven months. Admiral Brett Giroir will helm the agency on an acting basis until the new commissioner is confirmed.

US FDA Commissioner Search: Did Sharpless’ Hopes Just Go Up In Smoke?

US FDA Acting Commissioner Sharpless’ time in office may be rapidly running out. The Trump Administration appears ready to pick an outside candidate to run FDA, with MD Anderson’s Hahn now the apparent front-runner. A prominent Democratic Senator’s criticism of Sharpless and his response to vaping may be the final blow.

Three Candidates In Running To Become FDA Commissioner, Including Acting Chief Ned Sharpless

The Trump administration is seriously considering three candidates to become US Food and Drug Administration commissioner when the legally mandated 210-day term of acting commissioner Norman “Ned” Sharpless ends on 4 November.

Topics

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel